Indication
Secondary-progressive Multiple Sclerosis
2 clinical trials
3 products
1 drug
Clinical trial
Open-label, Single-blind, Observational, Comparative, Prospective, 36-month, Longitudinal, Controlled Study to Assess Efficacy of Siponimod (Mayzent®) on Microglia in Patients With Active Secondary Progressive Forms of Multiple SclerosisStatus: Completed, Estimated PCD: 2023-06-01
Product
MayzentProduct
OcrevusClinical trial
MACSiMiSE-BRAIN: Metformin add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination and Neurodegeneration: a Phase II Placebo-controlled Randomized Clinical TrialStatus: Recruiting, Estimated PCD: 2026-12-31
Product
Metformin HydrochlorideDrug
Varlilumab